UBX1325 shows sustained responses in patients with DME, wet AMD at 12 weeks
Patients with diabetic macular edema or wet age-related macular degeneration who received a single injection of UBX1325 demonstrated “strong and sustained responses” at 12 weeks, according to a press release from Unity Biotechnology.
UBX1325, a small molecule inhibitor of Bcl-xL, targets a different biologic pathway from anti-VEGF therapies. The treatment has been well tolerated in the phase 1 clinical trial through 12 weeks with no treatment-related adverse events or dose-limiting toxicities.
Across all doses, eight of 12 patients gained best corrected visual acuity ETDRS letters from baseline at 12 weeks. In high-dose groups, five of six patients showed a gain in ETDRS letters.
Six of 10 patients showed a decrease in central subfield thickness at 12 weeks, while three of five patients in the high-dose groups showed a decrease at 12 weeks.
“We are excited by the trajectory of the data showing both a rapid response and sustained improvements in vision and retinal structure in most patients through 12 weeks following a single injection of UBX1325,” Anirvan Ghosh, PhD, CEO of Unity, said in the release.
The company plans to share complete 24-week data from the original phase 1 cohort before the end of the year.
Read more about